Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jun 20, 2022 8:14am
233 Views
Post# 34768252

RE:RE:RE:RE:RE:Employee reviews

RE:RE:RE:RE:RE:Employee reviewsFGPstock ... lolll  Pretty simplistic and arrogant view that even Prof. McFarland would not agree on. 

A molecule alone is nothing.  Go ask Prof McFarland's  peers (Prof Glazier, Prof. Gasser, etc ...) that have come up with similar molecules but that never found a multidisciplinary team to make the whole thing work.


We owe it all to Sherri?  Not really, but she's clearly part of a team when you considered all the additional work out of her scope needed to have her molecule retain all its efficacy.  Dosimetry software was build from scratch, the decision to use of the proper light, reviewing the 1993 failure of Photofrin, etc ...  

One of those don't work properly and you don't make it globally.  In 1993  Photofrin had efficacy that got it FDA approval but because of another issue (impact on the bladder wall), urologists never used it.  

Even Prof. McFarland acknowledges that it's a multi-disciplinary work.  Dr. Rueck's innovation, all the work of Prof. Lilge, Prof. Betz, onboarding IBM and Intel, all the patents of Dr. Mandel, etc ...

Roger could have never pay attention to the request of Prof. McFarland back in 2010, persevering through all those many challenges, being involved in all the steps, convincing top minds, giving them all the lattitude to express all their talent, never cut-corners when SH posters were impatient, etc ...

Keep attributing the April 5 sudden drop to a press release missing bullet forms presentation when in fact it was simply short-sighted investors and shorts at work.  


<< Previous
Bullboard Posts
Next >>